Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Assets (2020 - 2025)

Mirum Pharmaceuticals has reported Assets over the past 6 years, most recently at $842.8 million for Q4 2025.

  • Quarterly results put Assets at $842.8 million for Q4 2025, up 25.65% from a year ago — trailing twelve months through Dec 2025 was $842.8 million (up 25.65% YoY), and the annual figure for FY2025 was $842.8 million, up 25.65%.
  • Assets for Q4 2025 was $842.8 million at Mirum Pharmaceuticals, up from $785.1 million in the prior quarter.
  • Over the last five years, Assets for MIRM hit a ceiling of $842.8 million in Q4 2025 and a floor of $222.2 million in Q1 2021.
  • Median Assets over the past 5 years was $545.1 million (2023), compared with a mean of $503.1 million.
  • Peak annual rise in Assets hit 95.47% in 2024, while the deepest fall reached 2.65% in 2024.
  • Mirum Pharmaceuticals' Assets stood at $294.7 million in 2021, then grew by 19.77% to $352.9 million in 2022, then skyrocketed by 83.23% to $646.6 million in 2023, then rose by 3.73% to $670.8 million in 2024, then rose by 25.65% to $842.8 million in 2025.
  • The last three reported values for Assets were $842.8 million (Q4 2025), $785.1 million (Q3 2025), and $725.8 million (Q2 2025) per Business Quant data.